دورية أكاديمية
Interleukin-11/IL-11 Receptor Promotes Glioblastoma Cell Proliferation, Epithelial-Mesenchymal Transition, and Invasion.
| العنوان: | Interleukin-11/IL-11 Receptor Promotes Glioblastoma Cell Proliferation, Epithelial-Mesenchymal Transition, and Invasion. |
|---|---|
| المؤلفون: | Stuart SF; Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia.; Fiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia., Curpen P; Townsville Hospital and Health Service, James Cook University, Townsville, QLD 4814, Australia., Gomes AJ; Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia., Lan MC; Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia., Nie S; Melbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science & Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3052, Australia., Williamson NA; Melbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science & Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3052, Australia., Kannourakis G; Fiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.; Federation University, Ballarat, VIC 3350, Australia., Morokoff AP; Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia.; Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia., Achuthan AA; Department of Medicine, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia., Luwor RB; Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia.; Fiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.; Federation University, Ballarat, VIC 3350, Australia. |
| المصدر: | Brain sciences [Brain Sci] 2024 Jan 17; Vol. 14 (1). Date of Electronic Publication: 2024 Jan 17. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101598646 Publication Model: Electronic Cited Medium: Print ISSN: 2076-3425 (Print) Linking ISSN: 20763425 NLM ISO Abbreviation: Brain Sci Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | Glioblastoma is highly proliferative and invasive. However, the regulatory cytokine networks that promote glioblastoma cell proliferation and invasion into other areas of the brain are not fully defined. In the present study, we define a critical role for the IL-11/IL-11Rα signalling axis in glioblastoma proliferation, epithelial to mesenchymal transition, and invasion. We identified enhanced IL-11/IL-11Rα expression correlated with reduced overall survival in glioblastoma patients using TCGA datasets. Proteomic analysis of glioblastoma cell lines overexpressing IL-11Rα displayed a proteome that favoured enhanced proliferation and invasion. These cells also displayed greater proliferation and migration, while the knockdown of IL-11Rα reversed these tumourigenic characteristics. In addition, these IL-11Rα overexpressing cells displayed enhanced invasion in transwell invasion assays and in 3D spheroid invasion assays, while knockdown of IL-11Rα resulted in reduced invasion. Furthermore, IL-11Rα-overexpressing cells displayed a more mesenchymal-like phenotype compared to parental cells and expressed greater levels of the mesenchymal marker Vimentin. Overall, our study identified that the IL-11/IL-11Rα pathway promotes glioblastoma cell proliferation, EMT, and invasion. |
| References: | ESMO Open. 2017 Feb 22;1(6):e000144. (PMID: 28912963) Cytokine Growth Factor Rev. 2015 Oct;26(5):489-98. (PMID: 26209885) J Pak Med Assoc. 2017 Sep;67(9):1410-1414. (PMID: 28924284) Cancer Cell. 2013 Aug 12;24(2):145-7. (PMID: 23948295) Int J Oncol. 2012 Aug;41(2):759-64. (PMID: 22614117) Cancers (Basel). 2018 Dec 19;10(12):. (PMID: 30572654) Clin Cancer Res. 2015 Jul 1;21(13):3041-51. (PMID: 25779950) J Exp Clin Cancer Res. 2019 Feb 8;38(1):63. (PMID: 30736824) Cell Prolif. 2020 May;53(5):e12771. (PMID: 32270546) Semin Immunol. 2014 Feb;26(1):54-74. (PMID: 24552665) Onco Targets Ther. 2018 Feb 07;11:731-742. (PMID: 29445288) Exp Cell Res. 2018 Jul 15;368(2):184-193. (PMID: 29709516) Neurosci Lett. 1995 Aug 25;196(3):153-6. (PMID: 7501271) Int J Mol Sci. 2023 Feb 08;24(4):. (PMID: 36834778) FEBS Lett. 2018 Mar;592(6):949-961. (PMID: 29427528) EBioMedicine. 2019 Sep;47:18-19. (PMID: 31402232) Biochem Soc Trans. 2019 Apr 30;47(2):625-638. (PMID: 30902924) PLoS One. 2013 Nov 11;8(11):e78728. (PMID: 24244348) mSphere. 2017 Jun 21;2(3):. (PMID: 28656174) J Exp Clin Cancer Res. 2018 Jul 25;37(1):168. (PMID: 30041669) J Cell Biochem. 2012 Nov;113(11):3353-62. (PMID: 22644863) Signal Transduct Target Ther. 2017 Sep 29;2:17040. (PMID: 29263927) Pathologe. 2020 Mar;41(2):163-167. (PMID: 32078699) Cancer Sci. 2015 May;106(5):592-7. (PMID: 25702890) Mol Cancer Ther. 2016 Nov;15(11):2609-2619. (PMID: 27535971) Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2105-2117. (PMID: 28630024) Oncogene. 2018 Mar;37(10):1386-1398. (PMID: 29321665) Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8065-8070. (PMID: 28698375) Contemp Oncol (Pozn). 2018 Mar;22(1A):81-85. (PMID: 29628799) J Clin Oncol. 2017 Jul 20;35(21):2402-2409. (PMID: 28640706) Cell Physiol Biochem. 2018;45(6):2213-2224. (PMID: 29550807) Ann Surg Oncol. 2006 Jun;13(6):802-8. (PMID: 16614887) Jpn J Clin Oncol. 2015 Feb;45(2):202-9. (PMID: 25420690) Oncotarget. 2015 Oct 20;6(32):32297-8. (PMID: 26452137) Clin Cancer Res. 2018 Sep 1;24(17):4187-4200. (PMID: 29444930) Clin Cancer Res. 2019 Jun 15;25(12):3643-3657. (PMID: 30824583) J Pharmacol Exp Ther. 2018 Apr;365(1):72-83. (PMID: 29437915) Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):. (PMID: 33846242) World J Gastroenterol. 2006 Jan 14;12(2):317-21. (PMID: 16482637) Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):873-82. (PMID: 17544000) Korean J Physiol Pharmacol. 2014 Oct;18(5):391-6. (PMID: 25352758) Tumour Biol. 2014 Nov;35(11):11467-72. (PMID: 25123265) PLoS One. 2017 Dec 18;12(12):e0189670. (PMID: 29253028) Nat Rev Cancer. 2021 Aug;21(8):481-499. (PMID: 34083781) Methods. 2001 Dec;25(4):402-8. (PMID: 11846609) Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076) Neurooncol Adv. 2023 May 12;5(1):vdad058. (PMID: 37313501) PLoS One. 2014 Mar 19;9(3):e92444. (PMID: 24647355) Neuro Oncol. 2013 Jan;15(1):112-21. (PMID: 23223340) Biochim Biophys Acta. 2009 Nov;1793(11):1623-33. (PMID: 19665497) Front Oncol. 2012 Aug 14;2:98. (PMID: 22912934) Front Pharmacol. 2018 Sep 13;9:879. (PMID: 30271342) Tumour Biol. 2015 Apr;36(4):2369-75. (PMID: 25524575) Cells. 2019 Sep 30;8(10):. (PMID: 31574953) Growth Factors. 2019 Apr;37(1-2):1-11. (PMID: 31161823) Cancer Cell. 2013 Aug 12;24(2):257-71. (PMID: 23948300) BMC Biotechnol. 2012 Mar 21;12:8. (PMID: 22433466) Clin Cancer Res. 2014 Nov 15;20(22):5579-88. (PMID: 25074610) Cancer Res. 2009 Mar 1;69(5):1995-9. (PMID: 19244100) N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009) J Biol Chem. 2020 Jun 12;295(24):8285-8301. (PMID: 32332100) |
| فهرسة مساهمة: | Keywords: EMT; glioblastoma; interleukin 11; invasion |
| تواريخ الأحداث: | Date Created: 20240122 Latest Revision: 20240128 |
| رمز التحديث: | 20240128 |
| مُعرف محوري في PubMed: | PMC10813507 |
| DOI: | 10.3390/brainsci14010089 |
| PMID: | 38248304 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!